This article is more than 5 years old. Information may no longer be current.

Medtronic announces launch of radiofrequency ablation system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Medtronic recently announced it has received FDA 510(k) clearance for its OsteoCool RF Ablation System.

The system offers simultaneous dual-probe capabilities and reportedly is the only system with cooled radiofrequency (RF) ablation technology that uses targeted high-frequency energy to destroy cancer cells, according to a press release.

“The OsteoCool System expands our pain therapies portfolio,” Julie Foster, general manager and vice president of the Pain Therapies business in the Neuromodulation division, which is part of the Restorative Therapies Group at Medtronic, said in the press release. “Our customers treat patients with Kyphon balloon kyphoplasty who also have painful spinal metastases. The OsteoCool system gives physicians a way to treat that pain in a single procedure with a familiar, minimally invasive technique.”

Medtronic acquired the OsteoCool technology and associated properties from Baylis Medical on Dec. 16, 2015 and partnered with the company. Terms of the acquisition were not released, according to the press release.

The device is currently pending CE mark approval.

Reference:

www.medtronic.com